Related Experiment Video
Updated: Jan 26, 2026

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
Published on: December 12, 2017
Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors
Arezoo Jamali1,2, Laura Kapitza1,3, Thomas Schaser4
1Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Vectofusin-1 enhances gene delivery for chimeric antigen receptor (CAR) T-cell therapy manufacturing. This improves receptor-targeted lentiviral vector efficiency without compromising T-cell function or selectivity.
Area of Science:
- Immunology
- Molecular Biology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T-cell therapy shows promise for cancer treatment but faces manufacturing challenges.
- Receptor-targeted lentiviral vectors (LVs) offer selective gene delivery to T-cell subtypes, potentially improving CAR T-cell generation.
- Current receptor-targeted LVs exhibit lower gene delivery rates compared to conventional vesicular stomatitis virus (VSV)-LVs.
Purpose of the Study:
- To investigate the effect of the transduction enhancer Vectofusin-1 on gene delivery efficiency using CD4- and CD8-targeted LVs.
- To assess if Vectofusin-1 impacts the target cell selectivity and killing capability of generated CAR T-cells.
- To compare gene delivery rates mediated by receptor-targeted LVs with and without Vectofusin-1 against conventional VSV-LVs.
Main Methods:
- Utilized CD4- and CD8-targeted lentiviral vectors (LVs) encoding a CD19-CAR and a truncated low-affinity nerve growth factor receptor (ΔLNGFR) reporter.
- Administered Vectofusin-1 to enhance transduction of human T-cells.
- Evaluated gene delivery rates, target cell selectivity, and cytotoxic activity of CAR T-cells post-transduction.
- Observed early transduction signals and analyzed the cause of off-target signals.
Main Results:
- Vectofusin-1 significantly enhanced gene delivery for both CD4- and CD8-targeted LVs.
- Enhanced gene delivery was achieved without compromising T-cell selectivity or killing capability.
- Vectofusin-1 substantially reduced gene delivery rates mediated by VSV-LVs.
- An early transient off-target signal was observed, attributed to cell-bound LVs with surface-incorporated ΔLNGFR, not transgene expression in off-target cells.
Conclusions:
- Vectofusin-1 is an effective transduction enhancer for receptor-targeted LVs in CAR T-cell manufacturing.
- Receptor-targeted LVs, augmented by Vectofusin-1, can achieve gene transfer rates comparable to conventional VSV-LVs.
- This approach improves CAR T-cell generation efficiency while maintaining therapeutic efficacy and specificity.
More Related Videos
Related Concept Videos
Horizontal Gene Transfer
Antibiotic Selection
Gene Therapy
What is Natural Selection?
Gene Flow
Types of Genetic Transfer Between Organisms

